tiprankstipranks
Arecor Therapeutics PLC (GB:AREC)
LSE:AREC
Holding GB:AREC?
Track your performance easily

Arecor Therapeutics PLC (AREC) Income Statement

3 Followers

Arecor Therapeutics PLC Income Statement

Last quarter (Q4 2022), Arecor Therapeutics PLC's total revenue was £―, a decrease of ― from the same quarter last year. In Q4, Arecor Therapeutics PLC's net income was £―. See Arecor Therapeutics PLC’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19
Total Revenue
-£ 3.54M£ 1.16M£ 1.70M£ 1.10M
Cost of Revenue
-----
Gross Profit
-£ 3.54M£ 1.16M£ 1.70M£ 1.10M
Operating Expense
-£ 14.06M£ 7.13M£ 5.13M£ 2.67M
Operating Income
-£ -10.53M£ -5.98M£ -3.43M£ -1.57M
Net Non Operating Interest Income Expense
-£ 83.00K£ 506.00K£ -84.00K£ -2.14K
Other Income Expense
-----
Pretax Income
-£ -10.55M£ -6.95M£ -3.51M£ -1.57M
Tax Provision
-£ -1.28M£ -776.00K£ -760.00K£ -293.00K
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
-£ -9.27M£ -6.17M£ -2.75M£ -1.28M
Basic EPS
-£ -0.32£ -0.27£ -0.10£ -0.05
Diluted EPS
-£ -0.32£ -0.27£ -0.10£ -0.05
Basic Average Shares
-£ 28.94M£ 23.03M£ 27.68M£ 27.68M
Diluted Average Shares
-£ 28.94M£ 23.03M£ 27.68M£ 27.68M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
-£ 14.06M£ -7.13M£ 5.13M£ 2.67M
Net Income From Continuing And Discontinued Operation
-£ -9.27M£ -6.17M£ -2.75M£ -1.28M
Normalized Income
-£ -11.66M£ -7.26M£ -2.75M£ -1.28M
Interest Expense
---£ 82.00K£ 7.63K
EBIT
-£ -10.52M£ -6.92M£ -3.43M£ -1.56M
EBITDA
-£ -10.18M£ -6.92M£ -3.26M£ -1.47M
Currency in GBP

Arecor Therapeutics PLC Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis